Advanced Biomedical Research

The association of anti-CCP1 antibodies with disease activity score 28 (DAS-28) in rheumatoid arthritis

Authors

1 Department of Rheumatology, Isfahan University of Medical Sciences, Alzahra Hospital, Soffe Avenue, Isfahan, Iran

2 Department of Community Medicine, Isfahan University of Medical Sciences, Alzahra Hospital, Soffe Avenue, Isfahan, Iran

Abstract

Background: Rheumatoid arthritis (RA) is one of the most frequent autoimmune diseases in the world which affect about 1% of people. Measurement of the anti-CCP1 antibody titer in these patients is one of the new tests that is available in our country and in the multiple studies has been shown to be more specific than rheumatoid factor in the diagnosis of RA (97%). This test becomes positive in early stage of disease and it has a high predictive value. The aim of our study was to determine the relationship between anti-CCP1 antibody and disease activity score 28 (DAS-28) in patients with rheumatoid arthritis.
Materials and Methods: A cross-sectional study was performed in 90 patients with RA for evaluating the relation between anti-CCP1 antibody titer and DAS-28, patients were selected by consecutive method; serum samples were collected from patients. Anti-CCP1 antibody was measured by the corresponding enzyme-linked immunosorbent assay. Additionally, erythrocyte sedimentation rates (ESR), rheumatoid factor (RF), DAS-28, visual analog scale (VAS) were determined in patients with RA. Statistical analysis performed with t-test and Pearson's correlations coefficient.
Results: Anti-CCP1 level was associated with DAS-28 (P<0.001, r=0.35). The largest linear correlation was between anti-CCP1 antibody levels and VAS; it means that higher titers of anti-CCP1 antibody are associated with more painful joints in our patients. The average of DAS-28 in our positive and negative anti-CCP1 antibody patients was 5.07±1.1 and 3.5±1.5, respectively (P<0.05).
Conclusion: There was moderate correlation between anti-CCP1 titer and DAS-28.

Keywords

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.  Back to cited text no. 2
[PUBMED]    
3. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002;14:115-20.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4. Olsen NJ, Stein CM. New drug for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5. Eggeland T, Munthe E. The role of the laboratory in rheumatology, rheumatoid factors. Clin Rheum Dis 1983;9:135-60.  Back to cited text no. 5
    
6. Smolen JS. Autoantibodies in rheumatoid arthritis. In: Van Venrooij WJ, Maini RN, editors. Manual of biological markers of disease, Section C1.1/1-C1.1/18. Dordrecht: Kluwer; 1996  Back to cited text no. 6
    
7. Thorsteinsson J, Bjfrnsson OJ, Kolbeinsson A, Allander E, Sigfusson N, Olafsson O. A population study of rheumatoid factor in Iceland. A 5 year follow-up of 50 women with rheumatoid factor (RF). Ann Clin Res 1975;7:183-94.  Back to cited text no. 7
    
8. Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undiVerentiated arthritis: A prospective cohort study. Arthritis Rheum 2004;50:709-15.  Back to cited text no. 8
[PUBMED]  [FULLTEXT]  
9. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic Citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.  Back to cited text no. 9
    
10. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting Wve year radiographic damage. Ann Rheum Dis 2003;62:120-6.  Back to cited text no. 10
[PUBMED]  [FULLTEXT]  
11. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.  Back to cited text no. 11
[PUBMED]  [FULLTEXT]  
12. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62:870.  Back to cited text no. 12
[PUBMED]  [FULLTEXT]  
13. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.  Back to cited text no. 13
[PUBMED]  [FULLTEXT]  
14. Finckh A, Liang MH. Anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis: Bayes clears the haze. Ann Intern Med 2007;146:816-7.  Back to cited text no. 14
[PUBMED]  [FULLTEXT]  
15. Emery P. The optimal management of early rheumatoid disease: The key to preventing disability. Br J Rheumatol 1994;33:765-8.  Back to cited text no. 15
[PUBMED]  [FULLTEXT]  
16. Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 205;64:196-201.  Back to cited text no. 16
    
17. Visser H. Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:55-72.  Back to cited text no. 17
[PUBMED]  [FULLTEXT]  
18. Kaarela K, Kauppi MJ, Lehtinen KE. The value of the ACR 1987 criteria in very early rheumatoid arthritis. Scand J Rheumatol 1995;24:279-81.  Back to cited text no. 18
[PUBMED]    
19. Saraux A, Berthelot JM, Chales G, Le HenaV C, Thorel JB, Hoang S, et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classiWcation of these patients two years later. Arthritis Rheum 2001;44:2485-91.  Back to cited text no. 19
    
20. Van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002;60:383-8.  Back to cited text no. 20
[PUBMED]  [FULLTEXT]  
21. Kirwan JR, Quilty B. Prognostic criteria in rheumatoid arthritis: Can we predict which patients will require specific antirheumatoid treatment? Clin Exp Rheumatol 1997;15(Suppl 17):S15-25.  Back to cited text no. 21
[PUBMED]    
22. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology 2006;45:478-80.  Back to cited text no. 22
[PUBMED]  [FULLTEXT]  
23. Glasnoviæ M, Bosnjak I, Vcev A, Soldo I, Glasnoviæ-Horvatiæ E, Soldo-Butkoviæ S, et al. Anti-citrullinated antibodies, radiological joint damages and their correlations with disease activity score (DAS28). Coll Antropol 2007;31:345-8.  Back to cited text no. 23
    
24. Papadopoulos NG, Tsiaousis GZ, Pavlitou-Tsiontsi A, Giannakou A, Galanopoulou VK. Does the Presence of Anti-CCP Auto antibodies and Their Serum Levels Influence the Severity and Activity in Rheumatoid Arthritis Patients? Clin Rev Allergy Immunol 2008;34:11-5.  Back to cited text no. 24
    
25. Greiner A, Plischke H, Kellner H, Gruber R. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005;1050:295-303.  Back to cited text no. 25
   
Advanced Biomedical Research
Volume 2012, July
July 2012
Pages 1-4